Market Cap 484.97M
Revenue (ttm) 0.00
Net Income (ttm) -117.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 357,700
Avg Vol 424,030
Day's Range N/A - N/A
Shares Out 66.99M
Stochastic %K 93%
Beta -0.06
Analysts Strong Sell
Price Target $22.80

Company Profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
jackcoltrain
jackcoltrain Jul. 4 at 10:47 PM
$ENGN $PLRX I think better than holding cash in a savings account for this year
0 · Reply
fantastex
fantastex Jul. 4 at 11:33 AM
$ENGN 20-25m cash Burn per quarter still 230m in the bank
0 · Reply
NFA_DYOR
NFA_DYOR Jul. 2 at 3:29 PM
$ENGN Cash is interesting but what's their burn rate? They'll probably finish this quick
1 · Reply
NFA_DYOR
NFA_DYOR Jul. 2 at 3:28 PM
$ENGN Bro chill Ghis is just phase 2 There's phase 3 to go
1 · Reply
Buy_SoFi
Buy_SoFi Jul. 2 at 12:00 PM
$TLTFF <----- 👀. Keep an eye on Theralase if you're in $CGON $IBRX $ENGN and looking for an undervalued cancer cure play. FDA rolling review for Ruvidar (NMIBC) about to be announced (Q3 2026), future market leader in HSV treatment and other cancer cures... These opportunities for "100x returns" don't come around very often. $MRK
0 · Reply
Buy_SoFi
Buy_SoFi Jun. 30 at 8:37 PM
$TLTFF <--- MAJOR NEWS!!! 💥 $100 million in financing now accessible! $IBRX $CGON $ENGN $MRK
0 · Reply
fantastex
fantastex Jun. 29 at 10:45 AM
$ENGN if the drug proves itself effective, this is a likely buyout candidate.
0 · Reply
fantastex
fantastex Jun. 27 at 10:35 PM
$ENGN July s coming....BLA
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 19 at 6:38 PM
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape https://ow.ly/3MRh50ZeJ4o Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors. $ENGN
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 19 at 4:12 PM
Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA https://ow.ly/le5L50ZeGrt enGene Therapeutics Inc. ( $ENGN ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock.
0 · Reply
Latest News on ENGN
enGene price target lowered to $4 from $6 at H.C. Wainwright

2026-06-16T10:06:52.000Z - 18 days ago

enGene price target lowered to $4 from $6 at H.C. Wainwright


enGene implements plan to reduce workforce by 50%

2026-06-15T13:10:35.000Z - 19 days ago

enGene implements plan to reduce workforce by 50%


enGene Therapeutics Earnings release: Q2 2026

Jun 15, 2026, 9:00 AM EDT - 19 days ago

enGene Therapeutics Earnings release: Q2 2026


enGene Therapeutics Quarterly report: Q2 2026

Jun 15, 2026, 9:00 AM EDT - 19 days ago

enGene Therapeutics Quarterly report: Q2 2026


enGene Therapeutics Transcript: AGM 2026

Jun 9, 2026, 8:30 AM EDT - 25 days ago

enGene Therapeutics Transcript: AGM 2026


enGene price target lowered to $2 from $9 at UBS

2026-05-14T15:24:03.000Z - 7 weeks ago

enGene price target lowered to $2 from $9 at UBS


enGene downgraded to Perform from Outperform at Oppenheimer

2026-05-08T16:22:56.000Z - 2 months ago

enGene downgraded to Perform from Outperform at Oppenheimer


enGene downgraded to Market Perform from Outperform at Leerink

2026-05-08T12:11:57.000Z - 2 months ago

enGene downgraded to Market Perform from Outperform at Leerink


enGene Therapeutics Proxy statement: Proxy filing

May 8, 2026, 8:00 AM EDT - 2 months ago

enGene Therapeutics Proxy statement: Proxy filing


enGene downgraded to Neutral from Buy at Guggenheim

2026-05-08T09:15:51.000Z - 2 months ago

enGene downgraded to Neutral from Buy at Guggenheim


enGene downgraded to Neutral from Overweight at Piper Sandler

2026-05-08T09:10:12.000Z - 2 months ago

enGene downgraded to Neutral from Overweight at Piper Sandler


enGene downgraded to Market Perform from Outperform at Citizens

2026-05-08T09:00:14.000Z - 2 months ago

enGene downgraded to Market Perform from Outperform at Citizens


enGene downgraded to Neutral from Buy at Guggenheim

2026-05-07T21:51:44.000Z - 2 months ago

enGene downgraded to Neutral from Buy at Guggenheim


enGene announces updated interim results from LEGEND cohort

2026-05-07T14:15:38.000Z - 2 months ago

enGene announces updated interim results from LEGEND cohort


enGene Therapeutics Transcript: Study result

May 7, 2026, 8:00 AM EDT - 2 months ago

enGene Therapeutics Transcript: Study result


enGene Therapeutics Slides: Study result

May 7, 2026, 8:00 AM EDT - 2 months ago

enGene Therapeutics Slides: Study result


enGene Therapeutics Press release: Study result

May 7, 2026, 8:00 AM EDT - 2 months ago

enGene Therapeutics Press release: Study result


enGene initiated with a Buy at WBB Securities

2026-04-13T11:21:48.000Z - 2 months ago

enGene initiated with a Buy at WBB Securities


enGene Therapeutics Slides: Corporate presentation

Apr 10, 2026, 7:00 AM EDT - 3 months ago

enGene Therapeutics Slides: Corporate presentation


enGene Announces Name Change to enGene Therapeutics Inc.

Apr 7, 2026, 8:00 AM EDT - 3 months ago

enGene Announces Name Change to enGene Therapeutics Inc.


enGene Therapeutics Earnings release: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 4 months ago

enGene Therapeutics Earnings release: Q1 2026


enGene Therapeutics Quarterly report: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 4 months ago

enGene Therapeutics Quarterly report: Q1 2026


enGene Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

enGene Therapeutics Slides: Corporate presentation


enGene to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:00 AM EST - 4 months ago

enGene to Participate in Upcoming Investor Conferences


enGene Therapeutics Registration statement: Registration Filing

Feb 19, 2026, 7:00 AM EST - 4 months ago

enGene Therapeutics Registration statement: Registration Filing


enGene Therapeutics Slides: Corporate presentation

Jan 9, 2026, 6:00 AM EST - 6 months ago

enGene Therapeutics Slides: Corporate presentation


enGene Therapeutics Annual report: Q4 2025

Dec 18, 2025, 4:00 PM EST - 7 months ago

enGene Therapeutics Annual report: Q4 2025


enGene Therapeutics Earnings release: Q4 2025

Dec 18, 2025, 4:00 PM EST - 7 months ago

enGene Therapeutics Earnings release: Q4 2025


enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 4:01 PM EST - 8 months ago

enGene Announces Proposed Public Offering of Common Shares


enGene Therapeutics Slides: Corporate Presentation

Nov 11, 2025, 6:00 PM EST - 8 months ago

enGene Therapeutics Slides: Corporate Presentation


enGene Therapeutics Transcript: Study Update

Nov 11, 2025, 8:00 AM EST - 8 months ago

enGene Therapeutics Transcript: Study Update


enGene Therapeutics Press release: Study Update

Nov 11, 2025, 8:00 AM EST - 8 months ago

enGene Therapeutics Press release: Study Update


enGene Therapeutics Slides: Study Update

Nov 11, 2025, 8:00 AM EST - 8 months ago

enGene Therapeutics Slides: Study Update


enGene Therapeutics Slides: Corporate Presentation

Nov 11, 2025, 7:00 AM EST - 8 months ago

enGene Therapeutics Slides: Corporate Presentation


enGene Named a BioSpace 2026 Best Places to Work Winner

Nov 4, 2025, 1:35 PM EST - 8 months ago

enGene Named a BioSpace 2026 Best Places to Work Winner


enGene Therapeutics Quarterly report: Q3 2025

Sep 11, 2025, 9:30 AM EDT - 10 months ago

enGene Therapeutics Quarterly report: Q3 2025


enGene Therapeutics Earnings release: Q3 2025

Sep 11, 2025, 9:30 AM EDT - 10 months ago

enGene Therapeutics Earnings release: Q3 2025


enGene Therapeutics Quarterly report: Q2 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q2 2025


enGene Therapeutics Earnings release: Q2 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Earnings release: Q2 2025


enGene Therapeutics Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Proxy statement: Proxy Filing


enGene Therapeutics Quarterly report: Q1 2025

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q1 2025


enGene Therapeutics Earnings release: Q1 2025

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Earnings release: Q1 2025


enGene Therapeutics Annual report: Q4 2024

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Annual report: Q4 2024


enGene Therapeutics Earnings release: Q4 2024

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Earnings release: Q4 2024


enGene Announces $60 Million Private Placement Financing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing


enGene Therapeutics Quarterly report: Q3 2024

Sep 10, 2024, 4:00 PM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q3 2024


enGene Therapeutics Earnings release: Q3 2024

Sep 10, 2024, 4:00 PM EDT - 1 year ago

enGene Therapeutics Earnings release: Q3 2024


enGene Therapeutics Quarterly report: Q2 2024

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q2 2024


enGene Therapeutics Earnings release: Q2 2024

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Earnings release: Q2 2024


enGene Therapeutics Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Proxy statement: Proxy Filing


/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:56 AM EDT - 2 years ago

/C O R R E C T I O N -- enGene Inc./


enGene Therapeutics Quarterly report: Q1 2024

Mar 11, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q1 2024


enGene Therapeutics Earnings release: Q1 2024

Mar 11, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Earnings release: Q1 2024


enGene Therapeutics Registration statement: Registration Filing

Feb 27, 2024, 7:00 AM EST - 2 years ago

enGene Therapeutics Registration statement: Registration Filing


jackcoltrain
jackcoltrain Jul. 4 at 10:47 PM
$ENGN $PLRX I think better than holding cash in a savings account for this year
0 · Reply
fantastex
fantastex Jul. 4 at 11:33 AM
$ENGN 20-25m cash Burn per quarter still 230m in the bank
0 · Reply
NFA_DYOR
NFA_DYOR Jul. 2 at 3:29 PM
$ENGN Cash is interesting but what's their burn rate? They'll probably finish this quick
1 · Reply
NFA_DYOR
NFA_DYOR Jul. 2 at 3:28 PM
$ENGN Bro chill Ghis is just phase 2 There's phase 3 to go
1 · Reply
Buy_SoFi
Buy_SoFi Jul. 2 at 12:00 PM
$TLTFF <----- 👀. Keep an eye on Theralase if you're in $CGON $IBRX $ENGN and looking for an undervalued cancer cure play. FDA rolling review for Ruvidar (NMIBC) about to be announced (Q3 2026), future market leader in HSV treatment and other cancer cures... These opportunities for "100x returns" don't come around very often. $MRK
0 · Reply
Buy_SoFi
Buy_SoFi Jun. 30 at 8:37 PM
$TLTFF <--- MAJOR NEWS!!! 💥 $100 million in financing now accessible! $IBRX $CGON $ENGN $MRK
0 · Reply
fantastex
fantastex Jun. 29 at 10:45 AM
$ENGN if the drug proves itself effective, this is a likely buyout candidate.
0 · Reply
fantastex
fantastex Jun. 27 at 10:35 PM
$ENGN July s coming....BLA
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 19 at 6:38 PM
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape https://ow.ly/3MRh50ZeJ4o Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors. $ENGN
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 19 at 4:12 PM
Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA https://ow.ly/le5L50ZeGrt enGene Therapeutics Inc. ( $ENGN ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock.
0 · Reply
notreload_ai
notreload_ai Jun. 18 at 11:53 AM
BofA initiates coverage on $IMMX with a Buy rating and $27 price target. RBC starts $PRAX with Outperform ($449 PT), while Cantor begins coverage on $RNA. Morgan Stanley downgrades $ENGN to Underweight. https://notreload.xyz/xy/bofa-buy-on-immx-rbc-cantor-bullish-on-prax-rna/
0 · Reply
fantastex
fantastex Jun. 16 at 3:50 PM
$ENGN sub 1.50 anytime. Will wait for that or 1.30 to hit
0 · Reply
notreload_ai
notreload_ai Jun. 15 at 3:59 PM
$ENGN is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing. https://notreload.xyz/xy/engene-cuts-50-workforce-and-halts-trial-enrollment/
0 · Reply
jotu
jotu Jun. 15 at 2:08 PM
$ENGN $285 m Cash vs $118 m Cap BLA 2h'26
2 · Reply
Gunnar1
Gunnar1 Jun. 15 at 1:33 PM
$ENGN Took a medium gain, they had mixed news today and I don't have the time to monitor it today. GLTA!
0 · Reply
STACKD0E
STACKD0E Jun. 15 at 1:24 PM
0 · Reply
Newcar
Newcar Jun. 9 at 5:06 PM
$ENGN When will there be the next news on this failed therapy?🤣 Waiting collapse under 1$
1 · Reply
Mr_GA
Mr_GA Jun. 4 at 2:33 PM
$ENGN https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
0 · Reply
G34
G34 Jun. 3 at 6:11 PM
$ENGN Some1 bought a loada calls today.
0 · Reply
jotu
jotu Jun. 3 at 3:10 PM
$ENGN Well its now a long hold as i keep adding about 10% from each scalp.
0 · Reply
Newcar
Newcar Jun. 3 at 2:49 PM
$ENGN In the next few months, with the confirmation of the failure of the efficacy of this therapy, it will lose at least another 50%
0 · Reply
Gunnar1
Gunnar1 May. 31 at 10:33 AM
$ENGN I'm using the weekly chart because IMO this is a long-term swing trade: Every time the price touched the blue trend line or came very close to it AND the KDJ was around 20 or below AND the RSI was at 30 or below, it subsequently rose by 150 to 260% within a timeframe of 21 to 154 days (see the price and date range marked in blue). In addition, there were smaller price increases between 50% and 114% independent of the trendline; see the price and date range marked in orange. What I’m doing now is somewhat arbitrary, but if you start with the lowest of the blue trendline-depending price increases (150%) and add the longest time period (154 days), then it could happen that at the current level — since we’re back in the range of the blue trendline — the price will be around $3.70 this autumn. Of course this is a rough estimate and there are no guarantees, but I would already be very satisfied with a 50 to 100% move. Take it with a grain of salt, I might be wrong, so you do you!
2 · Reply